Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune (Nasdaq: REPL) said company management will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Replimune (Nasdaq: REPL) said company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.
A simultaneous webcast will be available in the Investors section of replimune.com, and a replay will be available for 30 days following the conference.
Details
News Market Reaction – REPL
On Dec 18, the day this news came out, REPL closed 0.31% above the previous close.
Data tracked by StockTitan Argus for the Dec 18 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2025
- Scheduled conference presentation
- Presentation time
- 1:30 PM PT
- J.P. Morgan Healthcare Conference slot
- Replay duration
- 30 days
- Webcast replay availability
Historical Context
-
Updated RP1 plus nivolumab data with ORR and durable responses at SITC 2025.
-
Fiscal Q2 results and FDA acceptance of RP1 BLA resubmission with set PDUFA date.
-
FDA acceptance of RP1 BLA resubmission for advanced melanoma with PDUFA date.
-
Type A meeting feedback on CRL, with path under accelerated approval undetermined.
-
Scheduling Type A meeting and warning RP1 program viability without accelerated approval.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
oncolytic immunotherapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.
A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.